CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a monoclonal antibody that targets the Acyl CoA binding protein, which plays a role in tissue aging and cancer immunosuppression. By neutralizing this protein, the project aims to enhance immune responses against cancer, particularly in human and mouse models of various cancers.
Acyl CoA binding protien (ACBP, encoded by diazepam binding inhibitor, DBI) is a novel glucocorticoid-induced tissue hormone that contributes to tissue aging.
In still health individuals, the plasma concentrations of ACBP/DBI protein increase before cancer diagnosis. ACBP/DBI mediates immunosuppressive effects, meaning that its neutralization improves cancer immunosurveillance.
Therefore, ACBP/DBI might be considered as an immune checkpoint.
Thus far, we have demonstrated the immunostimulatory a…
UNIVERSITE PARIS CITE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
